Ratings CervoMed Inc.

Equities

CRVO

US15713L1098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
15.5 ^USD	-2.33%		-9.46%	+103.15%

Jul. 01	CervoMed Inc.(NasdaqCM:CRVO) added to Russell Small Cap Completeness Index	CI
Jul. 01	CervoMed Inc.(NasdaqCM:CRVO) added to Russell Microcap Growth Index	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CERVOMED INC.	+103.15%	128M	-
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B	B+
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B	B+
ARGENX SE	+17.23%	25.91B	B
BIONTECH SE	-24.11%	19.33B	B+
GENMAB A/S	-18.56%	16.17B	A-
BEIGENE, LTD.	-18.47%	15.6B	B
WUXI APPTEC CO., LTD.	-47.75%	14.65B	A-
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B	C+
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes